To scroll text in this page

Global Navigation
Global Navigation end

About Astellas

Start of the main text

2017 News Releases

About RSS

Global News

MSD submits application for approval of type-2 diabetes drug combining selective DPP-4 inhibitor and selective SGLT2 inhibitor

May 19, 2017

Tokyo, May 19, 2017 -MSD K.K. (President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; “Astellas”) today announced that MSD has submitted an application for marketing approval of a combination drug of the DPP-4 inhibitor sitagliptin phosphate hydrate (brand name: JANUVIA® Tablets) and the SGLT2 inhibitor ipragliflozin L-Proline (brand name: Suglat® Tablets) for the treatment of type-2 diabetes in Japan.


JANUVIA® Tablet is the first selective DPP-4 inhibitor in Japan manufactured and marketed by MSD. This once-daily inhibitor selectively inhibits DPP-4 and increases the active incretin levels, thus demonstrating glucose-dependent glucose-lowering effect. Suglat® Tablet is the first selective SGLT2 inhibitor in Japan manufactured and marketed by Astellas. With once-daily administration, it selectively inhibits SGLT2 and blocks renal glucose reuptake, thus demonstrating non-insulin-dependent glucose-lowering effect. The combination of these two drugs with different mechanisms of action for the treatment of type-2 diabetes is expected to reduce patients’ burden of taking drugs and improve their adherence. In a clinical study conducted to support this application, the drug has shown efficacy, safety and tolerability.


MSD and Astellas look forward to further contributing to the treatment of diabetes by offering a new treatment option for type-2 diabetes patients who have difficulty controlling blood sugar levels with monotherapy.





Printer-friendly version

Main Text end
Local Navigation
Local Navigation end
Related Links